420 LEXINGTON AVE,, NEW YORK, NY
Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Other Events
Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Reports Fiscal Year 2025 Financial Results and Provides Business Update
Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology Approves Amendment to 2024 Omnibus Stock Incentive Plan
Corporate Overview October 2025
Q4
FY 2024
Q2
Q1
Amended Annual Report
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Information Statement
Preliminary Information Statement
Definitive Proxy Statement
Definitive Additional Proxy Soliciting Materials
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
SEC Staff Correspondence